Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

5

Revenue 2014

Merck & Co.

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck & Co.'s 2013 sales performance.

Lighthouse Medical Communications appoints Andy Willmer as managing director

Lighthouse Medical Communications appoints Andy Willmer as managing director

Dennis O’Brien, CEO and co-founder of  Lucid, said: “Andy is a great fit with the team – and his history and experience in US and global pharma communications, both agency

CHMP recommends Teva's generic version of Astellas' Advagraf

CHMP recommends Teva's generic version of Astellas' Advagraf Meanwhile, Merck Sharp &Dohme ( MSD) also received an extension recommendation for Cubicin (daptomycin), an injectable antibiotic for adults and paediatric patients with staphylococcus aureus bacteraemia (SAB).

CETP inhibitor class finally dies as Merck abandons anacetrapib

CETP inhibitor class finally dies as Merck abandons anacetrapib Despite positive results in a large-scale trial, Merck &Co has decided not to file for approval of its cholesterol drug anacetrapib, saying the data simply isn’t strong enough. ... Merck - known as MSD outside North America - made the announcement in a

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Pfizer could raise ‘up to $15bn’ from consumer unit sale Pfizer is also not alone in its tinkering, and consumer health assets have been changing hands with some frequency in recent years, with Merck KGaA saying last month it is also ... 2015 asset-swap deal, and Bayer bought Merck &Co's consumer unit for

Lundbeck and Otsuka start phase III for Rexulti in bipolar

Lundbeck and Otsuka start phase III for Rexulti in bipolar Otsuka and co-development partner Lundbeck have started two phase III trials of their atypical antipsychotic Rexulti in bipolar disorder, potentially adding a third indication for the drug.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Merck
Global revenue 2014
1: Novartis
2: Pfizer
3: Roche
4: Sanofi
5: Merck & Co.
6: Johnson & Johnson
7: GlaxoSmithKline
8: AstraZeneca
9: Gilead Sciences
10: Takeda
11: AbbVie
12: Amgen
13: Teva
14: Lilly
15: Bristol-Myers Squibb
16: Bayer
17: Novo Nordisk
18: Astellas
19: Boehringer Ingelheim
20: Actavis
21: Otsuka
22: Daiichi Sankyo
23: Biogen Idec
24: Baxter
25: Merck KGaA
US revenue 2014
1: Gilead Sciences
2: Johnson & Johnson
3: Pfizer
4: Roche
5: Novartis
6: Amgen
7: Merck & Co.
8: Sanofi
9: AbbVie
10: Actavis
11: AstraZeneca
12: GlaxoSmithKline
13: Lilly
14: Bristol-Myers Squibb
15: Novo Nordisk
Oncology revenue 2014
1: Roche
2: Novartis
3: Celgene
4: Johnson & Johnson
5: Bristol-Myers Squibb
6: Lilly
7: Takeda
8: AstraZeneca
9: Merck & Co.
10: Amgen
11: Pfizer
12: Astellas
13: Bayer
14: Otsuka
15: Sanofi
16: Merck KGaA
17: Eisai
18: AbbVie
19: Pharmacyclics
20: Incyte
Immunology revenue 2014
1: AbbVie
2: Johnson & Johnson
3: Pfizer
4: Amgen
5: Merck & Co.
6: Astellas
7: Roche
8: Novartis
9: Bristol-Myers Squibb
10: Mitsubishi Tanabe
11: UCB
12: Hisamitsu
13: Daiichi Sankyo
14: Takeda
Cardiovascular revenue 2014
1: AstraZeneca
2: Sanofi
3: Merck & Co.
4: Daiichi Sankyo
5: Pfizer
6: Novartis
7: Bayer
8: Takeda
9: Boehringer Ingelheim
10: Astellas
11: Actelion
12: Johnson & Johnson
13: Shionogi
14: United Therapeutics
15: Bristol-Myers Squibb
16: Gilead Sciences
17: Otsuka
18: Roche
19: Lilly
20: The Medicines Company
Metabolic revenue 2014
1: Novo Nordisk
2: Sanofi
3: Merck & Co.
4: Lilly
5: AstraZeneca
6: Takeda
7: Novartis
8: Amgen
9: Bayer
10: Merck KGaA
11: Salix Pharmaceuticals
12: AbbVie
13: Dainippon Sumitomo Pharma
14: Kyowa Hakko Kirin
15: Mitsubishi Tanabe
Biologic revenue 2014
1: Roche
2: Amgen
3: Novo Nordisk
4: AbbVie
5: Sanofi
6: Johnson & Johnson
7: Pfizer
8: Merck & Co.
9: Lilly
10: Biogen Idec
11: Merck KGaA
12: GlaxoSmithKline
13: Bristol-Myers Squibb
14: Novartis
15: Bayer

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...
So how do you really engage with patients?
The most valuable insights from patient engagement are the most unexpected ones. Simple things, which may seem unimportant to you, may be the key to making patients’ lives easier and...
data
Avoiding data pitfalls in clinical research
Genomics sequencing and sensors will present new challenges...

Infographics